Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Arnold D, et al.
Published Date: 11/10/2023
Download Link: /wp-content/uploads/2023/10/Arnold-Thalamic-Volume_ECTRIMS-2023_Poster-Draft_Final.pdf
Download Text: Download
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top